10-Q: Relmada Therapeutics Reports Q2 2026 Results, Advances Pipeline

Relmada Therapeutics, Inc. filed its quarterly report for the period ending June 30, 2026, detailing continued investment in research and development for its lead candidates, NDV-01 and sepranolone, alongside significant cash reserves.

Summary

• Relmada Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026.
• The company incurred a net loss of $12.9 million for the quarter, compared to $9.9 million in the same period last year.
• Research and development expenses increased significantly to $8.4 million from $2.8 million year-over-year, driven by advancements in NDV-01 and sepranolone studies.
• General and administrative expenses decreased to $6.6 million from $7.4 million.
• As of June 30, 2026, the company held $219 million in total assets, including $206.4 million in short-term investments.
• Total liabilities were $12.5 million.
• Stockholders' equity stood at $206.6 million.
• The company expects to file IND applications for both NDV-01 and sepranolone with the FDA by the end of 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to continued net losses and significant R&D expenses, despite progress in pipeline development and substantial cash reserves.

Positives

• Significant increase in cash and short-term investments, totaling over $217 million as of June 30, 2026, providing ample runway.
• Successful acquisition of sepranolone and in-licensing of NDV-01, diversifying the development pipeline.
• Positive 12-month safety and efficacy data for NDV-01 in high-risk NMIBC, with a 76% complete response rate at 12 months.
• FDA alignment on key elements for the planned Phase 3 pivotal program for NDV-01.
• Sepranolone demonstrated potential to improve Tourette Syndrome symptoms in a Phase 2a study, with competitive tic reduction and improved quality of life.
• Intellectual property portfolio provides potential patent coverage beyond 2038 for sepranolone and beyond 2038 for NDV-01, with a provisional patent application for NDV-01 potentially extending coverage to April 2047.

Negatives

• Continued net losses, with a $12.9 million loss for the quarter and $31.9 million for the six months ended June 30, 2026.
• Significant increase in R&D expenses to $8.4 million for the quarter, reflecting ongoing clinical trial costs.
• Termination of the esmethadone (REL-1017) and psilocybin (REL-P11) programs.
• Loss per share of $0.11 for the quarter and $0.32 for the six months ended June 30, 2026.
• High stock-based compensation and stock appreciation rights expenses, particularly in general and administrative costs.

Risks

• The company has incurred losses and negative cash flows from operations since inception and expects to incur additional losses until it can generate significant revenue from commercialization.
• There can be no assurance that the company's research and development will be successfully completed or that any product will be approved or commercially viable.
• The company is subject to risks common to biotechnology companies, including dependence on collaborative arrangements, development by competitors, dependence on key personnel, protection of proprietary technology, and compliance with regulatory requirements.
• The company's existing cash and investments are expected to fund operations for at least 12 months, but future financing will be required for subsequent clinical trials.
• The company is developing NDV-01 for two separate indications, which increases complexity and potential costs.
• The FDA has agreed to rely on prior findings of safety for Gemzar and Taxotere for NDV-01, but regulatory approval is not guaranteed.

Future Outlook

Relmada Therapeutics expects to file IND applications with the FDA for both NDV-01 and sepranolone by the end of 2026. Upon IND clearance, the company anticipates initiating Phase 3 programs for NDV-01 (for two indications) and a Phase 2b study for sepranolone in Prader-Willi Syndrome. Management believes current cash and investments will fund operations for at least 12 months, with future financing to be evaluated for subsequent clinical trials.

Management Comments

• We substantially redesigned our development programs following a comprehensive strategic review in late 2024 and early 2025.
• We concluded in our review that the most promising path to create shareholder value was to lever our extensive drug development expertise and clinical operations capabilities by acquiring new development candidates, while terminating further work on esmethadone (d-methadone, dextromethadone or REL-1017).
• Management believes that the Company's existing cash and cash equivalents and short-term investments will enable it to fund operating expenses and capital expenditure requirements for at least 12 months from the issuance of these unaudited condensed consolidated financial statements.
• The Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company's business, financial condition, operating results, or cash flows.

Industry Context

StockSavvy.ai notes that Relmada's strategic shift towards acquiring new development candidates aligns with a common strategy in the competitive biotechnology sector to de-risk pipelines and accelerate growth. The focus on NDV-01 for NMIBC addresses a market need potentially exacerbated by BCG shortages, while sepranolone targets rare neurological disorders with significant unmet needs.

Comparison to Industry Standards

• The complete response rate of 76% at 12 months for NDV-01 in high-risk NMIBC is competitive, with the subpopulation of BCG-unresponsive patients showing a 80% CR rate at 12 months.
• Sepranolone's tic reduction of 28% (p=0.051) in Tourette Syndrome, while not statistically significant at the primary endpoint, shows positive trends in key secondary endpoints like quality of life and reduction in premonitory urge, which are important metrics in this indication.
• The company's R&D spending as a percentage of total operating expenses is high, typical for clinical-stage biotechnology firms focused on developing novel therapies.

Legal Proceedings

• The Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company's business, financial condition, operating results, or cash flows.

Stakeholder Impact

• Shareholders: Continued investment in R&D and pipeline development may lead to future value creation, but also carries inherent risks of clinical trial failures and regulatory hurdles. The substantial cash reserves provide a buffer.
• Employees: Stock-based compensation and stock appreciation rights are significant expenses, indicating a reliance on equity incentives for key personnel.
• Creditors: No significant debt is disclosed, suggesting minimal immediate impact on creditors.

Next Steps

• File United States Investigational New Drug (IND) applications with the FDA for NDV-01 by year-end 2026.
• File United States Investigational New Drug (IND) applications with the FDA for sepranolone by year-end 2026.
• Initiate Phase 3 programs for NDV-01 (two indications) upon IND clearance.
• Initiate a Phase 2b study for sepranolone in Prader-Willi Syndrome upon IND clearance.

Key Dates

Recommendation

Relmada Therapeutics demonstrates progress in its pipeline with promising early data for NDV-01 and sepranolone, supported by substantial cash reserves. However, the company continues to incur significant net losses and R&D expenses, and the success of its lead candidates is still subject to clinical and regulatory risks. The termination of previous programs also highlights the inherent uncertainties in drug development. Therefore, a 'hold' recommendation is appropriate, pending further clinical data and regulatory milestones.

Keywords

biotechnology, clinical-stage, drug development, NDV-01, sepranolone, NMIBC, Prader-Willi Syndrome, Tourette Syndrome